Ping Rawson
Chief Financial Officer
Replay available
Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call
Dyadic International, Inc. (NASDAQ: DYAI) Q4 2025 earnings conference call, held 2026-03-25. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Joe Hazelton
President and Chief Operating Officer
Mark Emelfarb
Chief Executive Officer
Matt Hewitt
Analyst, Craig-Hallum
John Vandermosten
Analyst, Zax
Tony Bowers
Analyst, IntroAct
Louis Titterton
Private Investor
Unidentified Participant
Participant
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Dyadic International, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.183 -- 00:00:05.189 Good evening and welcome to DIATIC's International Full Year 2025 Conference 00:00:05.189 -- 00:00:09.393 Call. Currently, all participants are in a listen-only mode. 00:00:09.393 -- 00:00:13.658 Following management's prepared remarks, there will be a brief question and answer session. 00:00:13.658 -- 00:00:19.265 As a reminder, this conference call is being recorded today, March 25, 2026. 00:00:19.265 -- 00:00:22.588 I would now like to turn the call over to Mrs. 00:00:22.588 -- 00:00:26.773 Ping Rawson, DIATIC's Chief Financial Officer. 00:00:26.773 -- 00:00:29.294 Please go ahead. 00:00:29.427 -- 00:00:34.815 Thank you, operator. Good evening and welcome everyone to Dyadic's full year 2025 00:00:34.815 -- 00:00:40.584 conference call. I hope you have had the opportunity to review Dyadic's press releases 00:00:40.584 -- 00:00:46.389 announcing financial results for the year ended December 31st, 2025. 00:00:46.392 -- 00:00:52.060 You may access our release and form 10K and the investor section of the company's website 00:00:52.060 -- 00:00:54.661 at dyadic.com. 00:00:54.965 -- 00:01:00.011 On today's call, Our President and Chief Operating Officer, Joe Hazelton, 00:01:00.011 -- 00:01:05.279 will review our full year 2025 business and corporate highlights and provide 00:01:05.279 -- 00:01:09.445 a commentary on the strategic direction of the business. 00:01:09.445 -- 00:01:14.452 Our CEO, Mark Emelfarb, will provide an update on our biopharmaceutical 00:01:14.452 -- 00:01:20.421 programs, and I will follow with a review of our financial results in more detail, 00:01:20.421 -- 00:01:24.676 after which we'll hold a brief Q&A session. 00:01:24.676 -- 00:01:29.041 At this time, I would like to inform you that certain commentary made i...